

Next Generation Sequencing Global Market

[Products (Instruments & Consumables, Services and Work Flow Products), Technology (Targeted Resequencing, Whole Exome Sequencing, RNA Sequencing, Whole Genome Sequencing, ChIP sequencing, De novo sequencing, and Methyl Sequencing), End Users (Academic Research, Hospitals & Clinics, Biotech/Pharma and Others) Applications {Clinical (Oncology, Genetic Screening, Infectious Diseases and Others), Non-Clinical (Oncology, Genetic Screening, Infectious Diseases, Drug & Biomarker discovery, Epidemiology, Agriculture and Others)}, Region (North America, Europe, APAC and RoW)],

– Forecast to 2020



Copyright © 2014 IQ4I

All Rights Reserved. This document contains highly confidential information and is the sole property of IQ4I. No part of it may be circulated, copied, quoted, or otherwise reproduced without the approval of IQ4I.

2014

**IQ4I Research &
Consultancy Pvt. Ltd.**

info@iq4i.com

www.iq4i.com

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY	17
2 INTRODUCTION	25
2.1 KEY TAKE AWAYS	25
2.2 REPORT DESCRIPTION	25
2.3 MARKETS COVERED	26
2.4 STAKEHOLDERS	28
2.5 RESEARCH METHODOLOGY	28
2.5.1 MARKET SIZE ESTIMATION.....	29
2.5.2 MARKET CRACKDOWN AND DATA TRIANGULATION	32
2.5.3 SECONDARY SOURCES	33
2.5.4 PRIMARY SOURCES	34
2.5.5 KEY DATA POINTS FROM SECONDARY SOURCES.....	34
2.5.6 KEY DATA POINTS FROM PRIMARY SOURCES.....	35
2.5.7 ASSUMPTIONS	35
3 MARKET ANALYSIS	36
3.1 INTRODUCTION	36
3.2 MARKET SEGMENTATION	37
3.3 FACTORS INFLUENCING MARKET	40
3.3.1 DRIVERS AND OPPORTUNITIES	41
3.3.1.1 REDUCED COST AND HIGH SPEED.....	41
3.3.1.2 INCREASED USAGE IN CLINICAL DIAGNOSIS.....	41
3.3.1.3 SWITCH TO NGS FROM MICROARRAY TECHNOLOGY.....	42
3.3.1.4 NEW & EMERGING APPLICATIONS OF NGS TECHNOLOGY.....	43
3.3.1.5 GROWTH OF PERSONALIZED MEDICINE AND BIOMARKER SEGMENTS.....	44
3.3.1.6 RISING DEMAND FOR NGS DISCOVERY TECHNOLOGY	45
3.3.1.7 INCREASED MEDICAL SPENDING	46
3.3.1.8 RISE IN INCIDENCE OF CHRONIC DISEASE.....	46
3.3.1.9 EMERGING TECHNOLOGIES.....	47

3.3.2	RESTRAINTS AND THREATS.....	52
3.3.2.1	COMPLICATIONS IN NGS DATA STORAGE.....	52
3.3.2.2	STANDARDIZATION OF NGS FOR DIAGNOSTIC APPLICATION	53
3.3.2.3	GRANTS AND FUNDING FOR NGS INFRASTRUCTURE.....	53
3.3.2.4	LACK OF SKILLED LABOR	54
3.3.2.5	HUGE DATA INTERPRETATION OF NGS.....	54
3.3.2.6	ETHICAL AND LEGAL ISSUES TO NGS	55
3.3.3	BURNING ISSUES	56
3.3.3.1	REDUCED COST LEADS TO COMPLEXITY IN DATA STORAGE	56
3.4	PORTER’S FIVE FORCE ANALYSIS	57
3.4.1	THREAT OF NEW ENTRANTS	57
3.4.2	THREAT OF SUBSTITUTES	57
3.4.3	BARGAINING POWER OF SUPPLIERS	57
3.4.4	BARGAINING POWER OF BUYERS	58
3.4.5	COMPETITIVE RIVALRY	59
3.5	REGULATORY AFFAIRS	59
3.5.1	U.S.....	59
3.5.2	EUROPE.....	60
3.5.3	CHINA.....	61
3.6	MARKET SHARE ANALYSIS BY MAJOR PLAYERS	62
4	NEXT GENERATION SEQUENCING MARKET, BY PRODUCTS	64
4.1	INTRODUCTION	64
4.2	INSTRUMENTS AND CONSUMABLES	66
4.3	SERVICES.....	68
4.4	WORKFLOW PRODUCTS	70
5	NEXT GENERATION SEQUENCING MARKET VALUE AND VOLUME ANALYSIS, BY TECHNOLOGY	73
5.1	INTRODUCTION	73
5.1.1	NGS PLATFORM INSTALLATION BASE.....	74
5.1.2	NGS MARKET REVENUE, BY TECHNOLOGY.....	76
5.1.3	NGS SAMPLE MARKET VOLUME, BY TECHNOLOGY	77
5.2	TARGETED RESEQUENCING	78
5.2.1	TARGETED RESEQUENCING MARKET REVENUE, BY REGION.....	79
5.2.2	TARGETED RESEQUENCING SAMPLES MARKET VOLUME, BY REGION.....	80
5.3	WHOLE EXOME SEQUENCING.....	80
5.3.1	WHOLE EXOME SEQUENCING MARKET REVENUE, BY REGION.....	81
5.3.2	WHOLE EXOME SEQUENCING SAMPLES MARKET VOLUME, BY REGION	82

5.4	RNA SEQUENCING	82
5.4.1	RNA SEQUENCING MARKET REVENUE, BY REGION	84
5.4.2	RNA SEQUENCING SAMPLES MARKET VOLUME, BY REGION	85
5.5	WHOLE GENOME SEQUENCING	85
5.5.1	WHOLE GENOME SEQUENCING MARKET REVENUE, BY REGION	87
5.5.2	WHOLE GENOME SEQUENCING SAMPLES MARKET VOLUME, BY REGION	88
5.6	CHIP SEQUENCING	88
5.6.1	CHIP SEQUENCING MARKET REVENUE, BY REGION	89
5.6.2	CHIP SEQUENCING SAMPLES MARKET VOLUME, BY REGION	90
5.7	DE NOVO SEQUENCING	90
5.7.1	DE NOVO SEQUENCING MARKET REVENUE, BY REGION	92
5.7.2	DE NOVO SEQUENCING SAMPLES MARKET VOLUME, BY REGION	93
5.8	METHYL SEQUENCING.....	93
5.8.1	METHYL SEQUENCING MARKET REVENUE, BY REGION	94
5.8.2	METHYL SEQUENCING SAMPLES MARKET VOLUME, BY REGION	95
6	NEXT GENERATION SEQUENCING MARKET, BY END USERS/LABORATORIES	96
6.1	INTRODUCTION	96
6.1.1	NGS MARKET REVENUE BY END-USERS/ LABORATORIES.....	98
6.1.2	NGS SAMPLES MARKET VOLUME BY END-USERS/ LABORATORIES.....	99
6.1.3	NGS LABORATORIES VOLUME MARKET BY END- USERS	100
6.1.4	NGS LABORATORIES VOLUME MARKET BY LAB TYPE.....	101
6.1.5	NGS LABORATORIES VOLUME MARKET BY REGION.....	102
6.2	ACADEMIC RESEARCH	102
6.2.1	ACADEMIC RESEARCH MARKET REVENUE BY REGION	103
6.2.2	ACADEMIC RESEARCH SAMPLES MARKET VOLUME BY REGION	104
6.3	HOSPITALS AND CLINICS	104
6.3.1	HOSPITALS AND CLINICS MARKET REVENUE BY REGION.....	106
6.3.2	HOSPITALS AND CLINICS SAMPLES MARKET VOLUME BY REGION.....	107
6.4	BIOTECH/PHARMACEUTICALS	107
6.4.1	BIOTECH/PHARMACEUTICALS MARKET REVENUE BY REGION.....	109
6.4.2	BIOTECH/PHARMACEUTICALS SAMPLES MARKET VOLUME BY REGION.....	110
6.5	OTHER END USERS	111
6.5.1	OTHER END-USERS MARKET REVENUE BY REGION.....	112
6.5.2	OTHER END-USERS SAMPLES MARKET VOLUME BY REGION.....	113

7 NEXT GENERATION SEQUENCING MARKET VALUE AND VOLUME ANALYSIS, BY APPLICATION AREA	114
7.1 INTRODUCTION	114
7.1.1 NGS MARKET REVENUE BY APPLICATION TYPE	116
7.1.2 NGS SAMPLES MARKET VOLUME BY APPLICATION TYPE	117
7.2 OVERALL APPLICATIONS MARKET	118
7.2.1 ONCOLOGY	118
7.2.1.1 NGS ONCOLOGY MARKET REVENUE BY APPLICATION TYPE	119
7.2.1.2 NGS ONCOLOGY MARKET REVENUE BY REGION	120
7.2.1.3 NGS ONCOLOGY SAMPLES MARKET VOLUME BY REGION	121
7.2.2 GENETIC SCREENING	121
7.2.2.1 NGS GENETIC SCREENING MARKET REVENUE BY APPLICATION TYPE	123
7.2.2.2 NGS GENETIC SCREENING MARKET REVENUE BY REGION	124
7.2.2.3 NGS GENETIC SCREENING SAMPLES MARKET VOLUME BY REGION	125
7.2.3 INFECTIOUS DISEASES	125
7.2.3.1 NGS INFECTIOUS DISEASES MARKET REVENUE BY REGION	127
7.2.3.2 NGS INFECTIOUS SAMPLES MARKET VOLUME BY REGION	128
7.2.4 DRUG AND BIOMARKER DISCOVERY	128
7.2.4.1 NGS DRUG AND BIOMARKER DISCOVERY MARKET REVENUE BY REGION	129
7.2.4.2 NGS DRUG AND BIOMARKER DISCOVERY SAMPLES MARKET VOLUME BY REGION	130
7.2.5 MOLECULAR EPIDEMIOLOGY	131
7.2.5.1 NGS MOLECULAR EPIDEMIOLOGY MARKET REVENUE BY REGION	132
7.2.5.2 NGS MOLECULAR EPIDEMIOLOGY SAMPLES MARKET VOLUME BY REGION	133
7.2.6 AGRICULTURE AND ANIMAL RESEARCH	133
7.2.6.1 NGS AGRICULTURE AND ANIMAL RESEARCH MARKET REVENUE BY REGION	135
7.2.6.2 NGS AGRICULTURE AND ANIMAL RESEARCH SAMPLES MARKET VOLUME BY REGION	136
7.2.7 OTHER APPLICATIONS	136
7.2.7.1 NGS OTHER APPLICATIONS MARKET REVENUE BY REGION	137
7.2.7.2 NGS OTHER APPLICATIONS SAMPLES MARKET VOLUME BY REGION	138
7.3 NGS CLINICAL AND NON-CLINICAL APPLICATIONS	139
7.3.1 INTRODUCTION	139
7.3.1.1 NGS MARKET REVENUE BY CLINICAL AND NON-CLINICAL APPLICATION	140
7.3.1.2 NGS SAMPLES MARKET VOLUME BY CLINICAL AND NON-CLINICAL APPLICATION	141
7.3.2 CLINICAL	142
7.3.2.1 NGS CLINICAL APPLICATION MARKET REVENUE, BY TYPE	142
7.3.2.2 NGS CLINICAL APPLICATION MARKET REVENUE, BY REGION	143

7.3.2.3	ONCOLOGY.....	144
7.3.2.3.1	NGS CLINICAL ONCOLOGY MARKET REVENUE BY REGION.....	144
7.3.2.4	GENETIC SCREENING.....	145
7.3.2.4.1	NGS CLINICAL GENETIC SCREENING MARKET REVENUE BY REGION.....	145
7.3.2.5	INFECTIOUS DISEASES.....	146
7.3.2.5.1	NGS CLINICAL INFECTIOUS DISEASES MARKET REVENUE BY REGION.....	146
7.3.2.6	OTHER CLINICAL APPLICATIONS.....	147
7.3.2.6.1	NGS OTHER CLINICAL APPLICATIONS MARKET REVENUE BY REGION.....	147
7.3.3	NON-CLINICAL.....	148
7.3.3.1	NGS NON-CLINICAL APPLICATION MARKET REVENUE, BY TYPE.....	148
7.3.3.2	NGS NON-CLINICAL APPLICATION MARKET REVENUE, BY REGION.....	149
7.3.3.3	ONCOLOGY.....	150
7.3.3.3.1	NGS NON-CLINICAL ONCOLOGY MARKET REVENUE BY REGION.....	150
7.3.3.4	GENETIC SCREENING.....	151
7.3.3.4.1	NGS NON-CLINICAL GENETIC SCREENING MARKET REVENUE BY REGION.....	151
7.3.3.5	INFECTIOUS DISEASES.....	152
7.3.3.5.1	NGS NON-CLINICAL INFECTIOUS DISEASES MARKET REVENUE BY REGION.....	152
7.3.3.6	DRUG AND BIOMARKER DISCOVERY.....	153
7.3.3.6.1	NGS DRUG AND BIOMARKER DISCOVERY MARKET REVENUE BY REGION.....	153
7.3.3.7	MOLECULAR EPIDEMIOLOGY.....	154
7.3.3.7.1	NGS MOLECULAR EPIDEMIOLOGY MARKET REVENUE BY REGION.....	154
7.3.3.8	AGRICULTURE AND ANIMAL RESEARCH.....	155
7.3.3.8.1	NGS AGRICULTURE AND ANIMAL RESEARCH MARKET REVENUE BY REGION.....	155
7.3.3.9	OTHER NON-CLINICAL APPLICATIONS.....	156
7.3.3.9.1	NGS OTHER NON-CLINICAL APPLICATIONS MARKET REVENUE BY REGION.....	156
8	GEOGRAPHIC ANALYSIS.....	157
8.1	INTRODUCTION.....	157
8.2	NORTH AMERICA.....	160
8.3	EUROPE.....	167
8.4	ASIA-PACIFIC.....	174
8.5	REST OF THE WORLD.....	182

9	COMPANY DEVELOPMENTS	189
9.1	INTRODUCTION	189
9.2	AGREEMENTS, PARTNERSHIP, COLLABORATION & JOINT VENTURES	191
9.3	NEW PRODUCT LAUNCHES	204
9.4	APPROVALS	215
9.5	MERGES & ACQUISITIONS	217
9.6	OTHER DEVELOPMENTS	218
10	MAJOR PLAYER PROFILES	222
10.1	AGILENT TECHNOLOGIES, INC.	222
10.1.1	OVERVIEW.....	222
10.1.2	FINANCIALS.....	223
10.1.3	PRODUCT PORTFOLIO.....	225
10.1.4	KEY DEVELOPMENTS	227
10.1.5	BUSINESS STRATEGY.....	230
10.1.6	SWOT ANALYSIS.....	231
10.2	BGI (BEIJING GENOMICS INSTITUTE)	232
10.2.1	OVERVIEW.....	232
10.2.2	FINANCIALS.....	232
10.2.3	PRODUCT PORTFOLIO.....	233
10.2.4	KEY DEVELOPMENTS	234
10.2.5	BUSINESS STRATEGY.....	240
10.2.6	SWOT ANALYSIS.....	241
10.3	BIOMATTERS LTD	242
10.3.1	OVERVIEW.....	242
10.3.2	FINANCIALS.....	242
10.3.3	PRODUCT PORTFOLIO.....	242
10.3.4	KEY DEVELOPMENTS	243
10.3.5	BUSINESS STRATEGY.....	245
10.3.6	SWOT ANALYSIS.....	246
10.4	GENOMATIX SOFTWARE GMBH	247
10.4.1	OVERVIEW.....	247
10.4.2	FINANCIALS.....	247
10.4.3	PRODUCT PORTFOLIO.....	248
10.4.4	KEY DEVELOPMENTS	248
10.4.5	BUSINESS STRATEGY.....	249
10.4.6	SWOT ANALYSIS.....	250
10.5	ILLUMINA, INC.	251

10.5.1	OVERVIEW.....	251
10.5.2	FINANCIALS.....	251
10.5.3	PRODUCT PORTFOLIO.....	253
10.5.4	KEY DEVELOPMENTS	255
10.5.5	BUSINESS STRATEGY.....	266
10.5.6	SWOT ANALYSIS.....	267
10.6	PACIFIC BIOSCIENCES OF CALIFORNIA INC.	268
10.6.1	OVERVIEW.....	268
10.6.2	FINANCIALS.....	268
10.6.3	PRODUCT PORTFOLIO.....	270
10.6.4	KEY DEVELOPMENTS	272
10.6.5	BUSINESS STRATEGY.....	276
10.6.6	SWOT ANALYSIS.....	277
10.7	QIAGEN N.V.....	278
10.7.1	OVERVIEW.....	278
10.7.2	FINANCIALS.....	278
10.7.3	PRODUCT PORTFOLIO.....	280
10.7.4	KEY DEVELOPMENTS	282
10.7.5	BUSINESS STRATEGY.....	284
10.7.6	SWOT ANALYSIS.....	285
10.8	HOFFMANN-LA ROCHE LTD.	286
10.8.1	OVERVIEW.....	286
10.8.2	FINANCIALS.....	286
10.8.3	PRODUCT PORTFOLIO.....	289
10.8.4	KEY DEVELOPMENTS	290
10.8.5	BUSINESS STRATEGY.....	292
10.8.6	SWOT ANALYSIS.....	293
10.9	STRAND LIFE SCIENCES PVT. LTD.....	294
10.9.1	OVERVIEW.....	294
10.9.2	FINANCIALS.....	294
10.9.3	PRODUCT PORTFOLIO.....	295
10.9.4	KEY DEVELOPMENTS	295
10.9.5	BUSINESS STRATEGY.....	296
10.9.6	SWOT ANALYSIS.....	297
10.10	THERMO FISHER SCIENTIFIC INC.	298
10.10.1	OVERVIEW.....	298
10.10.2	FINANCIALS.....	298
10.10.3	PRODUCT PORTFOLIO.....	300

LIST OF TABLES

TABLE 1	GLOBAL NGS MARKET REVENUE, BY PRODUCTS, (2012-2020) (\$MN).....	20
TABLE 2	GLOBAL NGS MARKET REVENUE, BY TECHNOLOGY, (2012-2020) (\$MN).....	21
TABLE 3	GLOBAL NGS MARKET REVENUE, BY END-USERS/LABORATORIES, (2012-2020) (\$MN).....	22
TABLE 4	GLOBAL NGS MARKET REVENUE, BY APPLICATION TYPE, (2012-2020) (\$MN).....	23
TABLE 5	GLOBAL NGS MARKET REVENUE, BY REGION, (2012-2020) (\$MN).....	24
TABLE 6	EMERGING COMPANIES.....	47
TABLE 7	GLOBAL NGS MARKET REVENUE, BY PRODUCTS, (2012-2020) (\$MN).....	66
TABLE 8	GLOBAL NGS INSTRUMENTS & CONSUMABLES MARKET REVENUE, BY REGION, (2012-2020) (\$MN).....	68
TABLE 9	GLOBAL NGS SERVICES MARKET REVENUE, BY REGION, (2012-2020) (\$MN).....	70
TABLE 10	GLOBAL NGS WORKFLOW PRODUCTS MARKET REVENUE, BY REGION, (2012-2020) (\$MN).....	71
TABLE 11	GLOBAL NGS MARKET REVENUE, BY TECHNOLOGY, (2012-2020) (\$MN).....	76
TABLE 12	GLOBAL NGS SAMPLE MARKET VOLUME, BY TECHNOLOGY, (2012-2020) (NO'S).....	77
TABLE 13	GLOBAL TARGETED RESEQUENCING MARKET REVENUE, BY REGION, (2012-2020) (\$MN).....	79
TABLE 14	GLOBAL TARGETED RESEQUENCING SAMPLES MARKET VOLUME, BY REGION, (2012-2020) (NO'S).....	80
TABLE 15	GLOBAL WHOLE EXOME SEQUENCING MARKET REVENUE, BY REGION, (2012-2020) (\$MN).....	81
TABLE 16	GLOBAL WHOLE EXOME SEQUENCING SAMPLES MARKET VOLUME, BY REGION, (2012-2020) (NO'S).....	82
TABLE 17	GLOBAL RNA SEQUENCING MARKET REVENUE, BY REGION, (2012-2020) (\$MN).....	84
TABLE 18	GLOBAL RNA SEQUENCING SAMPLES MARKET VOLUME, BY REGION, (2012-2020) (NO'S).....	85
TABLE 19	GLOBAL WHOLE GENOME SEQUENCING MARKET REVENUE, BY REGION, (2012-2020) (\$MN).....	87
TABLE 20	GLOBAL WHOLE GENOME SEQUENCING SAMPLES MARKET VOLUME, BY REGION, (2012-2020) (NO'S).....	88
TABLE 21	GLOBAL CHIP SEQUENCING MARKET REVENUE, BY REGION, (2012-2020) (\$MN).....	89
TABLE 22	GLOBAL CHIP SEQUENCING SAMPLES MARKET VOLUME, BY REGION, (2012-2020) (NO'S).....	90
TABLE 23	GLOBAL DE NOVO SEQUENCING MARKET REVENUE, BY REGION, (2012-2020) (\$MN).....	92
TABLE 24	GLOBAL DE NOVO SEQUENCING SAMPLES MARKET VOLUME, BY REGION, (2012-2020) (NO'S).....	93
TABLE 25	GLOBAL METHYL SEQUENCING MARKET REVENUE, BY REGION, (2012-2020) (\$MN).....	94
TABLE 26	GLOBAL METHYL SEQUENCING SAMPLES MARKET VOLUME, BY REGION, (2012-2020) (NO'S).....	95
TABLE 27	GLOBAL NGS MARKET REVENUE, BY END-USERS/LABORATORIES, (2012-2020) (\$MN).....	98
TABLE 28	GLOBAL NGS SAMPLES MARKET VOLUME, BY END-USERS/LABORATORIES, (2012-2020) (NO'S).....	99
TABLE 29	GLOBAL NGS LABORATORY MARKET VOLUME, BY END-USERS, (2012-2020) (NO'S).....	100
TABLE 30	GLOBAL NGS LABORATORIES MARKET VOLUME, BY TYPE, (2012-2020) (NO'S).....	101
TABLE 31	GLOBAL NGS LABORATORIES MARKET VOLUME, BY REGION, (2012-2020) (NO'S).....	102
TABLE 32	GLOBAL ACADEMIC RESEARCH MARKET NGS REVENUE, BY REGION, (2012-2020) (\$MN).....	103
TABLE 33	GLOBAL ACADEMIC RESEARCH NGS SAMPLES MARKET VOLUME, BY REGION, (2012-2020) (NO'S).....	104
TABLE 34	GLOBAL HOSPITALS AND CLINICS NGS MARKET REVENUE, BY REGION, (2012-2020) (\$MN).....	106

TABLE 35	GLOBAL HOSPITALS AND CLINICS NGS SAMPLES MARKET VOLUME, BY REGION, (2012-2020)(NO'S)	107
TABLE 36	GLOBAL BIOTECH/PHARMACEUTICALS NGS MARKET REVENUE, BY REGION, (2012-2020) (\$MN).....	109
TABLE 37	GLOBAL BIOTECH/PHARMACEUTICALS NGS SAMPLES MARKET VOLUME, BY REGION, (2012-2020)(NO'S)	110
TABLE 38	GLOBAL OTHER END USERS NGS MARKET REVENUE, BY REGION, (2012-2020) (\$MN).....	112
TABLE 39	GLOBAL OTHER END USERS NGS SAMPLES MARKET VOLUME, BY REGION, (2012-2020)(NO'S)	113
TABLE 40	GLOBAL NGS MARKET REVENUE, BY APPLICATION TYPE, (2012-2020) (\$MN).....	116
TABLE 41	GLOBAL NGS SAMPLES MARKET VOLUME, BY APPLICATION TYPE, (2012-2020) (NO'S)	117
TABLE 42	GLOBAL NGS MARKET REVENUE, BY ONCOLOGY APPLICATION, (2012-2020) (\$MN).....	119
TABLE 43	GLOBAL NGS ONCOLOGY MARKET REVENUE, BY REGION, (2012-2020) (\$MN).....	120
TABLE 44	GLOBAL NGS ONCOLOGY SAMPLES MARKET VOLUME, BY REGION, (2012-2020) (NO'S)	121
TABLE 45	GLOBAL NGS MARKET REVENUE, BY GENETIC SCREENING APPLICATION, (2012-2020) (\$MN).....	123
TABLE 46	GLOBAL NGS GENETIC SCREENING MARKET REVENUE, BY REGION, (2012-2020) (\$MN).....	124
TABLE 47	GLOBAL NGS GENETIC SCREENING SAMPLES MARKET VOLUME, BY REGION, (2012-2020) (NO'S).....	125
TABLE 48	GLOBAL NGS INFECTIOUS DISEASE MARKET REVENUE, BY REGION, (2012-2020) (\$MN).....	127
TABLE 49	GLOBAL NGS INFECTIOUS DISEASES SAMPLES MARKET VOLUME, BY REGION, (2012-2020) (NO'S).....	128
TABLE 50	GLOBAL NGS DRUG AND BIOMARKER DISCOVERY MARKET REVENUE, BY REGION, (2012-2020) (\$MN).....	129
TABLE 51	GLOBAL NGS DRUG AND BIOMARKER DISCOVERY SAMPLES MARKET VOLUME, BY REGION, (2012-2020) (NO'S).....	130
TABLE 52	GLOBAL NGS MOLECULAR EPIDEMIOLOGY MARKET REVENUE, BY REGION, (2012-2020) (\$MN).....	132
TABLE 53	GLOBAL NGS MOLECULAR EPIDEMIOLOGY SAMPLES MARKET VOLUME, BY REGION, (2012-2020) (NO'S).....	133
TABLE 54	GLOBAL NGS AGRICULTURE AND ANIMAL RESEARCH MARKET REVENUE, BY REGION, (2012-2020) (\$MN).....	135
TABLE 55	GLOBAL NGS AGRICULTURE AND ANIMAL RESEARCH SAMPLES MARKET VOLUME, BY REGION, (2012-2020) (NO'S).....	136
TABLE 56	GLOBAL NGS OTHER APPLICATIONS MARKET REVENUE, BY REGION, (2012-2020) (\$MN).....	137
TABLE 57	GLOBAL NGS OTHER APPLICATIONS SAMPLES MARKET VOLUME, BY REGION, (2012-2020) (NO'S).....	138
TABLE 58	GLOBAL NGS MARKET REVENUE, BY APPLICATION, (2012-2020) (\$MN).....	140
TABLE 59	GLOBAL NGS SAMPLES MARKET VOLUME BY APPLICATION, (2012-2020) (NO'S)	141
TABLE 60	GLOBAL NGS CLINICAL APPLICATION MARKET REVENUE, BY TYPE (2012-2020) (\$MN)	142
TABLE 61	GLOBAL NGS CLINICAL APPLICATION MARKET REVENUE, BY REGION, (2012-2020) (\$MN)	143
TABLE 62	GLOBAL NGS CLINICAL ONCOLOGY APPLICATION MARKET REVENUE, BY REGION, (2012-2020) (\$MN).....	144
TABLE 63	GLOBAL NGS CLINICAL GENETIC ENGINEERING APPLICATION MARKET REVENUE, BY REGION, (2012-2020) (\$MN).....	145
TABLE 64	GLOBAL NGS CLINICAL INFECTIOUS DISEASES APPLICATION MARKET REVENUE, BY REGION, (2012-2020) (\$MN).....	146

TABLE 65	GLOBAL NGS OTHER CLINICAL APPLICATION MARKET REVENUE, BY REGION, (2012-2020) (\$MN).....	147
TABLE 66	GLOBAL NGS NON-CLINICAL APPLICATION MARKET REVENUE, BY TYPE (2012-2020) (\$MN).....	148
TABLE 67	GLOBAL NGS NON-CLINICAL APPLICATION MARKET REVENUE, BY REGION, (2012-2020) (\$MN).....	149
TABLE 68	GLOBAL NGS NON-CLINICAL ONCOLOGY APPLICATION MARKET REVENUE, BY REGION, (2012-2020) (\$MN).....	150
TABLE 69	GLOBAL NGS NON-CLINICAL GENETIC ENGINEERING APPLICATION MARKET REVENUE, BY REGION, (2012-2020) (\$MN).....	151
TABLE 70	GLOBAL NGS NON-CLINICAL INFECTIOUS DISEASES APPLICATION MARKET REVENUE, BY REGION, (2012-2020) (\$MN).....	152
TABLE 71	GLOBAL NGS NON-CLINICAL DRUG AND BIOMARKER DISCOVERY APPLICATION MARKET REVENUE, BY REGION, (2012-2020) (\$MN).....	153
TABLE 72	GLOBAL NGS NON-CLINICAL MOLECULAR EPIDEMIOLOGY APPLICATION MARKET REVENUE, BY REGION, (2012-2020) (\$MN).....	154
TABLE 73	GLOBAL NGS NON-CLINICAL AGRICULTURE AND ANIMAL RESEARCH APPLICATION MARKET REVENUE, BY REGION, (2012-2020) (\$MN).....	155
TABLE 74	GLOBAL NGS OTHER NON-CLINICAL APPLICATION MARKET REVENUE, BY REGION, (2012-2020) (\$MN).....	156
TABLE 75	GLOBAL NGS MARKET REVENUE, BY REGION, (2012-2020) (\$MN).....	159
TABLE 76	NORTH AMERICAN NGS MARKET REVENUE, BY TECHNOLOGY, (2012-2020) (\$MN).....	161
TABLE 77	NORTH AMERICAN NGS SAMPLES MARKET VOLUME, BY TECHNOLOGY, (2012-2020) (NO'S).....	162
TABLE 78	NORTH AMERICAN NGS MARKET REVENUE, BY END-USERS/LABORATORIES, (2012-2020) (\$MN).....	163
TABLE 79	NORTH AMERICAN NGS SAMPLES MARKET VOLUME, BY END-USERS/LABORATORIES, (2012-2020) (NO'S).....	164
TABLE 80	NORTH AMERICAN NGS MARKET REVENUE, BY APPLICATION (2012-2020) (\$MN).....	165
TABLE 81	NORTH AMERICAN NGS MARKET REVENUE, BY APPLICATION TYPE (2012-2020) (\$MN).....	166
TABLE 82	EUROPEAN NGS MARKET REVENUE, BY TECHNOLOGY, (2012-2020) (\$MN).....	168
TABLE 83	EUROPEAN NGS SAMPLES MARKET VOLUME, BY TECHNOLOGY, (2012-2020) (NO'S).....	169
TABLE 84	EUROPEAN NGS MARKET REVENUE, BY END-USERS/LABORATORIES, (2012-2020) (\$MN).....	170
TABLE 85	EUROPEAN NGS SAMPLES MARKET VOLUME, BY END-USERS/LABORATORIES, (2012-2020) (NO'S).....	171
TABLE 86	EUROPEAN NGS MARKET REVENUE, BY APPLICATION, (2012-2020) (\$MN).....	172
TABLE 87	EUROPEAN NGS MARKET REVENUE, BY APPLICATION TYPE, (2012-2020) (\$MN).....	173
TABLE 88	ASIA-PACIFIC NGS MARKET REVENUE, BY TECHNOLOGY, (2012-2020) (\$MN).....	176
TABLE 89	ASIA-PACIFIC NGS SAMPLES MARKET VOLUME, BY TECHNOLOGY, (2012-2020) (NO'S).....	177
TABLE 90	ASIA-PACIFIC NGS MARKET REVENUE, BY END-USERS/LABORATORIES, (2012-2020) (\$MN).....	178
TABLE 91	ASIA-PACIFIC NGS SAMPLES MARKET VOLUME, BY END-USERS/LABORATORIES, (2012-2020) (NO'S).....	179
TABLE 92	ASIA-PACIFIC NGS MARKET REVENUE, BY APPLICATION, (2012-2020) (\$MN).....	180
TABLE 93	ASIA-PACIFIC NGS MARKET REVENUE, BY APPLICATION TYPE, (2012-2020) (\$MN).....	181
TABLE 94	REST OF THE WORLD NGS MARKET REVENUE, BY TECHNOLOGY, (2012-2020) (\$MN).....	183
TABLE 95	REST OF THE WORLD NGS SAMPLES MARKET VOLUME, BY TECHNOLOGY, (2012-2020) (NO'S).....	184

TABLE 96	REST OF THE WORLD NGS MARKET REVENUE, BY END-USERS/LABORATORIES, (2012-2020) (\$MN).....	185
TABLE 97	REST OF THE WORLD NGS SAMPLES MARKET VOLUME, BY END-USERS/LABORATORIES, (2012-2020) (NO'S).....	186
TABLE 98	REST OF THE WORLD NGS MARKET REVENUE, BY APPLICATION, (2012-2020) (\$MN).....	187
TABLE 99	REST OF THE WORLD NGS MARKET REVENUE, BY APPLICATION TYPE, (2012-2020) (\$MN).....	188
TABLE 100	AGREEMENTS, PARTNERSHIP, COLLABORATION & JOINT VENTURES (2011-2014).....	191
TABLE 101	NEW PRODUCT LAUNCHES (2011-2014).....	204
TABLE 102	APPROVALS (2011-2014).....	215
TABLE 103	MERGES & ACQUISITIONS (2011-2014).....	217
TABLE 104	OTHER DEVELOPMENTS (2011-2014).....	219
TABLE 105	AGILENT TECHNOLOGIES, INC.: TOTAL REVENUE AND R&D EXPENSES (2011-2013) (\$MN).....	223
TABLE 106	AGILENT TECHNOLOGIES, INC.: TOTAL REVENUE, BY SEGMENTS, (2011-2013) (\$MN).....	223
TABLE 107	AGILENT TECHNOLOGIES, INC.: TOTAL REVENUE, BY GEOGRAPHY, (2011-2013) (\$MN).....	224
TABLE 108	ILLUMINA INC: TOTAL REVENUE AND R&D EXPENSES (2011-2013) (\$MN).....	251
TABLE 109	ILLUMINA INC: TOTAL REVENUE, BY GEOGRAPHY, (2011-2013) (\$MN).....	252
TABLE 110	PACIFIC BIOSCIENCES: TOTAL REVENUE AND R&D EXPENSES (2011-2013) (\$MN).....	268
TABLE 111	PACIFIC BIOSCIENCES: TOTAL REVENUE, BY SEGMENT, (2011-2013) (\$MN).....	269
TABLE 112	PACIFIC BIOSCIENCES: TOTAL REVENUE, BY GEOGRAPHY, (2011-2013) (\$MN).....	270
TABLE 113	QIAGEN'S: TOTAL REVENUE AND R&D EXPENSES, (2011-2013) (\$MN).....	278
TABLE 114	QIAGEN'S: TOTAL REVENUE, BY SEGMENTS, (2011-2013) (\$N).....	279
TABLE 115	QIAGEN'S: TOTAL REVENUE, BY GEOGRAPHY, (2011-2013) (\$MN).....	280
TABLE 116	ROCHE'S: TOTAL REVENUE AND OPERATING R&D EXPENSES, (2011-2013) (\$BN).....	286
TABLE 117	ROCHE'S: TOTAL REVENUE, BY SEGMENTS, (2011-2013) (\$BN).....	287
TABLE 118	ROCHE'S: DIAGNOSTICS REVENUE, BY SEGMENTS, (2011-2013) (\$BN).....	288
TABLE 119	ROCHE'S: TOTAL REVENUE, BY GEOGRAPHY (2011-2013) (\$BN).....	289
TABLE 120	THERMO FISHER SCIENTIFIC INC.: TOTAL REVENUE AND R&D EXPENSES (2011-2013) (\$BN).....	298
TABLE 121	THERMO FISHER SCIENTIFIC INC.: TOTAL REVENUE, BY SEGMENTS (2011-2013) (\$BN).....	299
TABLE 122	THERMO FISHER SCIENTIFIC INC.: TOTAL REVENUE, BY GEOGRAPHY (2011-2013) (\$BN).....	300

LIST OF FIGURES

FIGURE 1	GLOBAL NGS MARKET SCENARIO, BY REGION (2012-2020)	19
FIGURE 2	RESEARCH METHODOLOGY: NEXT GENERATION SEQUENCING MARKET	29
FIGURE 3	NGS MARKET: TOP-DOWN AND BOTTOM-UP APPROACH	30
FIGURE 4	NGS MARKET: FORECASTING MODEL	31
FIGURE 5	NGS MARKET: MARKET CRASHDOWN AND DATA TRIANGULATION	32
FIGURE 6	NGS MARKET: MARKET SEGMENTATION	37
FIGURE 7	MARKET DYNAMICS	40
FIGURE 8	NGS MARKET: PORTER'S ANALYSIS	58
FIGURE 9	GLOBAL NGS MARKET SHARE, BY KEY PLAYER'S (2013)	62
FIGURE 10	GLOBAL NGS MARKET SHARE, BY PRODUCTS (2012 - 2020)	65
FIGURE 11	NGS PLATFORM INSTALLATION BASE (2013)	74
FIGURE 12	NGS TECHNOLOGY MARKET SCENARIO, (2013 - 2020)	75
FIGURE 13	GLOBAL NGS LABORATORIES VOLUME MARKET, BY END-USERS (2012 - 2020)	97
FIGURE 14	GLOBAL NGS MARKET SHARE, BY APPLICATION (2013 V'S 2020)	115
FIGURE 15	GLOBAL NGS APPLICATION MARKET SHARE 2020 (NON-CLINICAL V'S CLINICAL)	139
FIGURE 16	GLOBAL NGS MARKET SCENARIO, BY REGION (2012 - 2020)	158
FIGURE 17	KEY GRWOTH STRATEGIES, (2012 - 2014)	190
FIGURE 18	SWOT ANALYSIS: AGILENT TECHNOLOGIES INC	231
FIGURE 19	SWOT ANALYSIS: BGI (BEIJING GENOMICS INSTITUTE)	241
FIGURE 20	SWOT ANALYSIS: BIOMATTERS LTD	246
FIGURE 21	SWOT ANALYSIS: GENOMATIX SOFTWARE GMBH	250
FIGURE 22	SWOT ANALYSIS: ILLUMINA, INC	267
FIGURE 23	SWOT: PACIFIC BIOSCIENCES OF CALIFORNIA, INC	277
FIGURE 24	SWOT: QIAGEN.N.V	285
FIGURE 25	SWOT: HOFFMANN-LA ROCHE LTD	293
FIGURE 26	SWOT: STRAND LIFE SCIENCES PVT. LTD	297
FIGURE 27	SWOT: THERMO FISHERS SCIENTIFIC, INC	303

1.1 REPORT DESCRIPTION

Next generation sequencing market is one of the fastest growing segments in the genomics market with an estimated CAGR of around 21% in the next five years. The research study includes the market assessment of various products, technologies, applications, and end-users. The report is definitely one of its kind, includes the data pertaining to the NGS sample volume market analysis by technology, end-users, and applications. The report also includes the installation base of various NGS platforms across the regions. Market analysis of labs performing NGS across the world segmented by lab type such as small, medium and large core.

The major factors such as rapid adoption of this technology by researchers and its usability as a substitute of microarray technology in addition to its higher throughput, increased accuracy, and affordable costs are driving the next generation sequencing market growth. However, factors such as reducing capital expenditure from academic institutions and huge dependability on grants funding from the government are hampering the next generation sequencing market growth. In addition, the analysis of large amount of data generated by sequencers, and data storage and management is posing a major challenge. The growth opportunities of this market include cloud computing, rising demand for pre-sequencing, developments in NGS fully integrated instruments and rising nanopore sequencing technology. There is a huge opportunity for this technology in the field of drug discovery, personalized medicine, agricultural and animal research.

Among the technology market targeted re-sequencing accounted for the largest share in 2013. The fastest growing technology is whole genome sequencing which has the highest CAGR of more than 25% during the forecast period. In the end users segment academic research holds the largest share in 2013. The fastest growing segment is hospitals and clinics during the forecast period. The highest CAGR is due to rising collaborations among hospitals, research institutes and NGS manufacturers leading to immediate transformation of NGS into applications.

The North American region accounts for the largest share of the next generation sequencing market. The European and Asian markets are also expected to grow due to the favorable funding from the government to adopt this technology. The major factors contributing to this market growth include rising adoption by new customers, rising adoption of high-throughput sequencing platforms by government organizations such as Biotechnology and Biological

Sciences Research Council (BBSRC) (U.K.) and NHGRI (National Human Genome Research Institute) (U.S.).

The key players dominating in the next generation sequencing market include Illumina Inc. (U.S.), Life Technologies Corporation (U.S.), Roche Holding AG. (Switzerland), Pacific Biosciences of California Inc. (U.S.), Ambry Genetics Corp. (U.S.), Axseq Technologies Inc. (U.S.), Beijing Genomics Institute (China), GeneDx (U.S.), Fluidigm Corp. (U.S.), Foundation Medicine Inc. (U.S.), Good Start Genetics Inc. (U.S.), Helicos BioSciences Corp. (U.S.), Knome Inc. (U.S.), NABsys Inc. (U.S.), Oxford Nanopore Technologies Ltd. (U.K.), Pathogenica Inc. (U.S.), and QIAGEN N.V. (The Netherlands).


Among the platforms Illumina accounted for the largest market share in 2013. Some of the most widely used platforms for NGS sequencing are Roche/454 Life Technologies (Pyrosequencing), the Illumina/Solexa Genome Analyzer (Sequencing by synthesis) the Applied Biosystems SOLiD System (sequencing by ligation), the Helicos, Heliscope (single molecule sequencing) and Pacific Biosciences SMRT (single molecule real time sequencing). Whole genome sequencing, targeted re-sequencing, de novo sequencing, RNA-Seq, ChIP-Seq and methyl-Seq are the major applications that use NGS data analysis tools and services.

The report provides an in depth market analysis of the above mentioned segments across the following regions:

- North America
- Europe
- Asia-Pacific
- Rest of the World (RoW)

FIGURE 1

NGS PLATFORM INSTALLATION BASE (2013)



Source: National Human Genome Research Institute (NHGRI), National Centre for Genomic Resources (NCGR), Genome Science Centre (GSC), Association of Clinical Research Professionals (ACRP), American Genetic Association (AGA), ASGT, NRCGEB, WHO, and Industry Expert Interviews

TABLE 1

**GLOBAL NGS SAMPLES MARKET VOLUME,
BY PLATFORM, (2012-2020) (NO'S)**


Platform	2012	2013	2014	2020	CAGR % (2014-2020)
Illumina	XX	XX	1,810,608	XX	XX
Thermofisher Scientific	XX	XX	XX	XX	XX
Roche	XX	XX	XX	XX	40.0
Pacific Biosciences	XX	XX	XX	XX	XX
Polonator -Dover systems	1,328	XX	XX	XX	XX
Others	XX	XX	XX	1,291,254	XX
Total	XX	XX	XX	XX	XX

Source: National Human Genome Research Institute (NHGRI), National Centre for Genomic Resources (NCGR), Genome Science Centre (GSC), Association of Clinical Research Professionals (ACRP), American Genetic Association (AGA), ASGT, NRCGEB, WHO, and Industry Expert Interviews

Illumina commanded the largest share of XX% of the global next generation sequencing samples market. It accounted for XX samples in 2013 growing at a CAGR of XX% from 2014 to 2020. Other platforms are expected to grow at the highest CAGR of XX% during the forecast period.

FIGURE 2

NGS TECHNOLOGY MARKET SCENARIO, (2013 - 2020)



Source: National Human Genome Research Institute (NHGRI), National Centre for Genomic Resources (NCGR), Genome Science Centre (GSC), Association of Clinical Research Professionals (ACRP), American Genetic Association (AGA), ASGT, NRCGEB, WHO, and Industry Expert Interviews

TABLE 2

**GLOBAL WHOLE GENOME SEQUENCING MARKET REVENUE,
BY REGION, (2012-2020) (\$MN)**

Region	2012	2013	2014	2020	CAGR % (2014-2020)
North America	XX	XX	XX	360.2	XX
Europe	XX	XX	XX	XX	XX
Asia-Pacific	XX	XX	XX	XX	XX
RoW	XX	XX	XX	XX	22.1
Total	126.9	XX	XX	XX	XX

Source: National Human Genome Research Institute (NHGRI), National Centre for Genomic Resources (NCGR), Genome Science Centre (GSC), Association of Clinical Research Professionals (ACRP), American Genetic Association (AGA), ASGT, NRCGEB, WHO, and Industry Expert Interviews

North America accounted for the largest revenue of \$XX million of the global whole genome sequencing technology market in 2013. It is expected to grow at a CAGR of XX% from 2014 to 2020 to reach \$XX million by 2020. Asia-Pacific is expected to grow at the highest CAGR of XX% during the forecast period.

TABLE 3

**GLOBAL NGS SAMPLES MARKET VOLUME, BY END-
USERS/LABORATORIES, (2012-2020) (NO'S)**

End Users	2012	2013	2014	2020	CAGR % (2014-2020)
Academic Research	XX	XX	XX	XX	XX
Hospitals and Clinics	XX	XX	XX	XX	37.8
Biotech/Pharmacy	XX	XX	XX	1,250,130	XX
Others	XX	XX	XX	XX	XX
Total	1,328,076	XX	XX	XX	XX

Source: National Human Genome Research Institute (NHGRI), National Centre for Genomic Resources (NCGR), Genome Science Centre (GSC), Association of Clinical Research Professionals (ACRP), American Genetic Association (AGA), ASGT, NRCGEB, WHO, and Industry Expert Interviews

Academic Research commanded the largest share of XX% of the global next generation sequencing samples market. It accounted for XX samples in 2013 growing at a CAGR of XX% from 2014 to 2020. Hospitals and clinics are expected to grow at the highest CAGR of XX% during the forecast period.

TABLE 4

**GLOBAL NGS LABORATORIES MARKET VOLUME,
BY TYPE, (2012-2020) (NO'S)**

Lab Type	2012	2013	2014	2020	CAGR % (2014-2020)
Small Core	XX	XX	XX	XX	XX
Medium Core	XX	XX	XX	XX	31.7
Large Core	934	XX	XX	4,731	XX
Total	XX	XX	XX	XX	XX

Source: National Human Genome Research Institute (NHGRI), National Centre for Genomic Resources (NCGR), Genome Science Centre (GSC), Association of Clinical Research Professionals (ACRP), American Genetic Association (AGA), ASGT, NRCGEB, WHO, and Industry Expert Interviews

Large core labs commanded for the largest share of XX% accounting for XX labs of the global next generation sequencing laboratories market in 2013. It is expected to grow at a CAGR of XX% from 2014 to 2020 to reach XX labs by 2020. Medium core labs are expected to grow at the highest CAGR of XX% during the forecast period.

1.1.1 RESEARCH SOURCES

TABLE 5


NEXT GENERATION SEQUENCING MARKET: RESEARCH SOURCES

Primary Sources	Secondary Sources
<ul style="list-style-type: none"> • Supply Side: Top-level Executives, Marketing Managers, Sales Managers, Regional Managers • Demand Side: Hospital Medical Directors, Laboratory Managers, Research Scientists, Principal Scientists, Purchase/Procurement Managers, Laboratory Technicians, Academic Research • Others: Independent Consultants and Freelancers 	<ul style="list-style-type: none"> • IQ4I Repository • NGS Company-Specific annual reports, SEC filings, corporate presentations & Press releases • Associations and Groups : World Health Organization (WHO), National Human Genome Research Institute (NHGRI), National Centre for Genomic Resources (NCGR), Genome Science Centre (GSC), ACRP, AGA, ASGT and NRCGEB • Paid Sources : Factiva, OneSource, Hoovers, Bloomberg • Social Networking & Databases: LinkedIn, Melt-Water, Zintro

1.2 RESEARCH METHODOLOGY

FIGURE 3

NEXT GENERATION SEQUENCING MARKET: RESEARCH APPROACH



1.2.1 MARKET SIZE ESTIMATION

The global Next Generation Sequencing market size, its different segments and sub-segments is analyzed using both top-down and bottom-up approaches. The market size and revenue calculated using research methodology involves primary and secondary research of major players in the market, factors influencing the market, market segmentation and geographical market scenario.

Secondary research of major players include the study of their annual and financial reports, press release while primary research involves interviews from the supply side (CEOs, directors, strategic growth managers, international/regional marketing managers, and marketing executives) and the demand side (reference laboratory heads, hospitals, and purchase managers).

Primary and secondary sources helped in verification of percentage shares, splits, and breakdowns. This data is consolidated with detailed inputs and presented in this report.

FIGURE 4

NEXT GENERATION SEQUENCING MARKET: TOP-DOWN AND BOTTOM-UP APPROACH





FIGURE 5

NEXT GENERATION SEQUENCING MARKET: FORECASTING MODEL



1.2.2 MARKET BREAKDOWN & DATA TRIANGULATION

FIGURE 6

NEXT GENERATION SEQUENCING MARKET: MARKET BREAKDOWN & DATA TRIANGULATION



Disclaimer: IQ4I strategic analysis services are limited publications containing valuable market information provided to a select group of customers in response to orders. Our customers acknowledge, when ordering, that IQ4I strategic analysis services are for our customers' internal use and not for general publication or disclosure to third parties. Quantitative market information is based primarily on interviews and therefore, is subject to fluctuation.

IQ4I does not endorse any vendor, product or service depicted in its research publications. IQ4I strategic analysis publications consist of the opinions of IQ4I' research and should not be construed as statements of fact. IQ4I disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.

IQ4I takes no responsibility for any incorrect information supplied to us by manufacturers or users.

All trademarks, copyrights and other forms of intellectual property belong to their respective owners and may be protected by copyright. Under no circumstance may any of these be reproduced in any form without the prior written agreement of their owner.

No part of this strategic analysis service may be given, lent, resold or disclosed to non-customers without written permission.

Reproduction and/or transmission in any form and by any means including photocopying, mechanical, electronic, recording or otherwise, without the permission of the publisher is prohibited.

For information regarding permission, contact:

Tel: +91 80 60500229

Email: satish.birudukota@IQ4I.com